caa a22 4500 605491658 CHVBK 20210128100511.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s10147-015-0812-9 doi (NATIONALLICENCE)springer-10.1007/s10147-015-0812-9 Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population [Elektronische Daten] [Yasunobu Hashimoto, Toshio Takagi, Tsunenori Kondo, Junpei Iizuka, Hirohito Kobayashi, Kenji Omae, Kazuhiko Yoshida, Kazunari Tanabe] Objective: We compared the clinical features and prognosis of renal cell carcinoma (RCC) between patients on hemodialysis (RCC-HD) and those in the general population (RCC-general). Methods: We included a total of 1,794 patients who underwent surgery (RCC-HD, 408; RCC-general, 1,386) and analyzed the clinical characteristics and oncological outcomes using a stage-for-stage analysis between the two groups. Results: In the RCC-HD group, the mean duration of dialysis before surgery was 120months. Compared to the RCC-general group, the RCC-HD group tended to be younger (55 vs. 60years, p<0.0001) and more predominately male (84% vs. 70%, p<0.0001), and the tumor size was smaller in this group (39 vs. 49mm, p<0.0001). The pathological characteristics of the RCC-HD group included a higher frequency of papillary tumors (22% vs. 5%, p<0.0001) and stage I tumors (82% vs. 68%, p<0.0001). During the follow-up period, 39 of patients (10%) in the RCC-HD group and 193 patients (14%) in the RCC-general group died of cancer. The patients on hemodialysis had better cancer-specific survival (CSS) than their counterparts (p=0.0292) in the univariable analysis, but no significance was found in the multivariable analysis. In the stage-for-stage analysis, the 5-year CSS was similar between the two groups for each stage. Conclusions: CSS appeared to be better in the RCC-HD group than in the RCC-general group, which may be associated with the higher incidence of stage I disease in the RCC-HD group. The comparable CSS between the groups in the stage-for-stage analysis supports this finding. Japan Society of Clinical Oncology, 2015 Kidney neoplasm nationallicence Prognosis nationallicence Nephrectomy nationallicence Hemodialysis nationallicence RCC : Renal cell carcinoma nationallicence ESRD : End-stage renal disease nationallicence HD : Hemodialysis nationallicence CSS : Cancer-specific survival nationallicence ACDK : Acquired cystic disease of kidney nationallicence Hashimoto Yasunobu Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut Takagi Toshio Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut Kondo Tsunenori Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut Iizuka Junpei Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut Kobayashi Hirohito Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut Omae Kenji Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut Yoshida Kazuhiko Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut Tanabe Kazunari Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 1035-1041 1341-9625 20:5<1035 2015 20 10147 https://doi.org/10.1007/s10147-015-0812-9 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0812-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hashimoto Yasunobu Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut NATIONALLICENCE 700 1- Takagi Toshio Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut NATIONALLICENCE 700 1- Kondo Tsunenori Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut NATIONALLICENCE 700 1- Iizuka Junpei Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut NATIONALLICENCE 700 1- Kobayashi Hirohito Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut NATIONALLICENCE 700 1- Omae Kenji Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut NATIONALLICENCE 700 1- Yoshida Kazuhiko Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut NATIONALLICENCE 700 1- Tanabe Kazunari Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 1035-1041 1341-9625 20:5<1035 2015 20 10147